GO:0031701 angiotensin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031701 (angiotensin receptor binding) is a molecular function defined as binding to an angiotensin receptor.
• Angiotensin receptors include AT1, AT2, and AT4 subtypes, which are bound by angiotensin II, angiotensin IV, and related ligands [1, 3, 8].
• The binding interaction is central to blood pressure regulation, fluid homeostasis, and cardiovascular disease pathology [2, 7].
• Mutagenesis and modeling studies have mapped the agonist and antagonist binding sites on the AT1 receptor.
• Altered angiotensin receptor binding is implicated in hypertension, pulmonary hypertension, and kidney disease [5, 6, 7].
• CRISPR-based models (KO, point mutation, knock-in, overexpression) enable precise dissection of receptor-ligand interactions [1, 4].
Description
Angiotensin receptor binding (GO:0031701) is a molecular function that describes the interaction between a ligand and any angiotensin receptor. This binding event is the first step in the renin-angiotensin system (RAS) signaling cascade, which regulates blood pressure, electrolyte balance, and vascular tone [1, 7]. The primary ligands include angiotensin II, which binds AT1 and AT2 receptors, and angiotensin IV, which binds the AT4 receptor [1, 3, 8]. Researchers study this term to understand how structural variations in ligands or receptors affect binding affinity and downstream signaling, with implications for cardiovascular drug development [2, 4]. The binding characteristics of angiotensin receptors have been extensively characterized in tissues such as kidney and lung, revealing subtype-specific expression and regulation [5, 7]. Mutagenesis studies have identified key residues in the AT1 receptor that determine agonist and antagonist binding specificity. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0031701, its mechanisms, associated genes, and experimental approaches.
angiotensin receptor binding At A Glance
| GO ID | GO:0031701 |
|---|---|
| GO term | angiotensin receptor binding |
| Ontology | molecular_function |
| Synonym | angiotensin receptor ligand |
| Major function | Binding to angiotensin receptors, initiating or blocking downstream signaling |
| Receptor subtypes | AT1, AT2, AT4 [1, 3, 8] |
| Primary ligands | Angiotensin II, angiotensin IV, and analogs [1, 3] |
| Tissue distribution | Kidney, lung, vascular smooth muscle, brain, adrenal gland [5, 7] |
| Disease relevance | Hypertension, pulmonary hypertension, kidney disease [2, 5, 7] |
What Is GO:0031701?
According to the Gene Ontology, GO:0031701 (angiotensin receptor binding) is defined as the molecular function of binding to an angiotensin receptor. This term encompasses the selective interaction between a ligand (such as angiotensin II, angiotensin III, angiotensin IV, or synthetic analogs) and any member of the angiotensin receptor family, including AT1, AT2, and AT4 subtypes [1, 3, 8]. The binding is non-covalent and reversible, and it initiates conformational changes that lead to receptor activation or blockade. The synonym 'angiotensin receptor ligand' reflects the role of the binding entity.
Why Is angiotensin receptor binding Important in Cell Biology?
Angiotensin receptor binding is a critical molecular event in the renin-angiotensin system, which controls blood pressure and fluid homeostasis [1, 7]. Dysregulation of this binding contributes to hypertension, heart failure, and kidney disease, making it a prime target for therapeutic intervention [2, 6]. Understanding the structural basis of ligand-receptor interactions informs the design of antagonists like candesartan and losartan [2, 4]. Moreover, receptor binding studies in animal models of pulmonary hypertension reveal adaptive changes that may guide treatment strategies. Thus, GO:0031701 is central to both basic cardiovascular biology and clinical pharmacology.
• Regulates blood pressure and electrolyte balance through the renin-angiotensin system [1, 7].
• Mediates the effects of angiotensin II, a potent vasoconstrictor [1, 8].
• Target of antihypertensive drugs such as candesartan and other ARBs [2, 6].
• Altered binding in pulmonary hypertension models indicates disease progression.
• Involved in kidney function and renal hemodynamics.
• AT4 receptor binding by angiotensin IV influences memory and neuronal functions.
• Mutagenesis studies provide insights into receptor activation mechanisms.
• Receptor subtype selectivity determines physiological outcomes [1, 8].
• Binding affinity changes can lead to drug resistance or altered efficacy.
• Provides a model for studying G protein-coupled receptor pharmacology.
Molecular Mechanism of angiotensin receptor binding
Ligand recognition and binding site
In simple terms: The ligand fits into a specific pocket on the receptor like a key in a lock.
Angiotensin II and related peptides bind to the AT1 receptor through a binding pocket formed by transmembrane helices. Mutagenesis studies have identified critical residues such as Lys199, His256, and Asp281 that interact with the ligand's C-terminal carboxylate and side chains. The binding is stereospecific and involves ionic and hydrophobic interactions. For the AT4 receptor, angiotensin IV binds with high affinity, but the exact binding site is less characterized.
Receptor conformational changes
In simple terms: Once the ligand binds, the receptor changes shape to transmit a signal inside the cell.
Ligand binding induces conformational changes in the AT1 receptor, particularly in transmembrane helix 6 and 7, leading to G protein activation. Antagonists like candesartan stabilize an inactive conformation, preventing these changes [2, 6]. The binding kinetics of antagonists can be tight and long-lasting, as shown for AT1 receptor antagonists.
Subtype-specific binding
In simple terms: Different receptor subtypes bind different ligands or have different effects.
AT1 and AT2 receptors both bind angiotensin II but have distinct functions and tissue distributions [1, 8]. AT1 mediates vasoconstriction and cell growth, while AT2 often opposes these effects. The AT4 receptor binds angiotensin IV and is involved in neuronal functions. Subtype-specific binding is determined by sequence differences in the ligand-binding pocket [1, 8].
Regulation of binding affinity
In simple terms: The strength of binding can be adjusted by cellular factors.
Receptor phosphorylation, internalization, and interaction with accessory proteins can modulate binding affinity. In disease states such as pulmonary hypertension, receptor density and binding characteristics change. For example, monocrotaline-induced pulmonary hypertension alters lung angiotensin receptor binding.
Key Genes Involved in GO:0031701 angiotensin receptor binding
The following genes encode receptors and ligands directly involved in angiotensin receptor binding (GO:0031701).
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGTR1 | Angiotensin II receptor type 1; binds angiotensin II and mediates vasoconstriction | Primary target of antihypertensive drugs; mutagenesis studies map binding site |
| AGTR2 | Angiotensin II receptor type 2; often opposes AT1 effects | Subtype-specific binding and signaling [1, 8] |
| AGTRAP | Angiotensin II receptor-associated protein; modulates receptor trafficking | Regulates receptor surface expression and binding |
| ACE | Angiotensin-converting enzyme; generates angiotensin II | Determines ligand availability for binding |
| ACE2 | Angiotensin-converting enzyme 2; converts angiotensin II to angiotensin (1-7) | Balances ligand levels and receptor binding |
| REN | Renin; initiates angiotensinogen cleavage | Upstream regulator of ligand production |
| AGT | Angiotensinogen; precursor of angiotensin peptides | Source of ligands for receptor binding |
| ANPEP | Aminopeptidase N; generates angiotensin IV | Produces AT4 receptor ligand |
| ENPEP | Glutamyl aminopeptidase; generates angiotensin III | Modulates ligand repertoire |
| MAS1 | Mas receptor; binds angiotensin (1-7) | Counter-regulatory axis |
| AGTR1 | AT1 receptor variants | Polymorphisms affect binding affinity and drug response |
| AGTR2 | AT2 receptor variants | Genetic variants linked to cardiovascular phenotypes |
| LNPEP | Leucyl/cystinyl aminopeptidase; produces angiotensin IV | Regulates AT4 ligand levels |
| THOP1 | Thimet oligopeptidase; degrades angiotensin peptides | Controls ligand availability |
| MME | Neprilysin; degrades angiotensin peptides | Affects binding by altering ligand concentrations |
| AGTR1 | AT1 receptor interacting proteins | Modulate receptor function |
| AGTR2 | AT2 receptor interacting proteins | Modulate receptor function |
How Is angiotensin receptor binding Regulated?
Angiotensin receptor binding is regulated at multiple levels. Ligand availability is controlled by the enzymatic cascade of the renin-angiotensin system, including renin, ACE, and ACE2. Receptor expression and surface availability are modulated by transcriptional regulation, internalization, and interaction with proteins like AGTRAP. In disease states such as pulmonary hypertension, receptor binding characteristics change, as shown in monocrotaline-treated rats. Additionally, antagonist binding can be tight and long-lasting, effectively reducing receptor availability. These regulatory mechanisms ensure fine-tuned control of angiotensin signaling.
angiotensin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGTR1 | Hypertension | Knockout or point-mutation mice; overexpression in vascular smooth muscle cells |
| AGTR1 | Pulmonary hypertension | Monocrotaline-treated rats; lung-specific KO |
| AGTR2 | Cardiac hypertrophy | KO mice; knock-in of human variants |
| AGTR1 | Kidney disease | Kidney-specific KO; tagged knock-in for imaging |
| AGTR2 | Neurological disorders | Brain-specific overexpression; AT4 receptor KO |
Hypertension and cardiovascular disease
Angiotensin receptor binding is directly implicated in hypertension. Overactivation of AT1 receptors by angiotensin II leads to vasoconstriction and sodium retention, elevating blood pressure [1, 7]. Antagonists like candesartan block this binding, reducing blood pressure. Genetic variants in AGTR1 can alter binding affinity and influence drug response [2, 4].
Pulmonary hypertension
In monocrotaline-induced pulmonary hypertension, lung angiotensin receptor binding characteristics change, suggesting a role in disease progression. Altered receptor density or affinity may contribute to vascular remodeling.
Kidney disease
Angiotensin II receptor subtypes in the kidney regulate renal hemodynamics and sodium excretion. Dysregulated binding contributes to diabetic nephropathy and chronic kidney disease. AT1 antagonists are used to slow disease progression.
Neurological disorders
The AT4 receptor binds angiotensin IV and is involved in memory and neuronal plasticity. Altered binding may contribute to cognitive decline, though mechanisms are still under investigation.
From angiotensin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AGTR1 mediate angiotensin II-induced vasoconstriction? | AGTR1 knockout mice |
| How do point mutations in AGTR1 affect ligand binding? | Point-mutation knock-in mice or cell lines |
| What is the effect of AGTR1 overexpression in the heart? | Cardiac-specific overexpression mice |
| Can we visualize AT1 receptor trafficking? | Tagged knock-in (e.g., GFP-AGTR1) |
| What is the role of AT2 receptor in blood pressure regulation? | AGTR2 knockout rats |
| How does angiotensin IV binding to AT4 affect memory? | AT4 receptor knockout mice |
How to Study the angiotensin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Binding affinity (Kd) and receptor density (Bmax) | Characterizing receptor subtypes in tissues [5, 7] |
| Site-directed mutagenesis | Effect of specific residues on ligand binding | Mapping binding site of AT1 receptor |
| CRISPR knockout | Loss of receptor function | Validating receptor role in blood pressure regulation |
| CRISPR knock-in | Effect of point mutations or tags on binding | Studying human variants or receptor trafficking |
| Competition binding | Antagonist affinity and binding kinetics | Evaluating drug candidates like candesartan [2, 6] |
| Immunohistochemistry | Receptor localization and expression | Tissue distribution of AT1/AT2 receptors |
| Surface plasmon resonance | Real-time binding kinetics | Measuring ligand-receptor interactions |
| Molecular modeling | 3D structure of binding pocket | Predicting ligand interactions |
Radioligand binding assays
Radioligand binding assays using 125I-angiotensin II are the gold standard for measuring angiotensin receptor binding affinity and density [5, 6]. These assays can distinguish receptor subtypes using selective antagonists [1, 8].
Mutagenesis and structural modeling
Site-directed mutagenesis combined with three-dimensional receptor modeling has identified key residues involved in ligand binding and receptor activation. This approach reveals the molecular determinants of agonist and antagonist binding.
CRISPR-based genetic models
CRISPR/Cas9 technology enables the generation of knockout, point-mutation, and knock-in models to study angiotensin receptor binding in vivo [1, 4]. These models help dissect the contribution of specific residues or receptor subtypes to physiological and pathological processes.
Pharmacological characterization
Antagonist binding kinetics, such as tight binding of AT1 antagonists, are studied using competition binding and functional assays. Candesartan, for example, exhibits insurmountable antagonism due to tight binding [2, 6].
How CRISPR Can Be Used to Study GO:0031701 angiotensin receptor binding
Knockout
CRISPR knockout of AGTR1 or AGTR2 in cell lines or animal models abolishes receptor expression, allowing researchers to study the loss of angiotensin receptor binding and its downstream effects. For example, AGTR1 knockout mice show reduced blood pressure response to angiotensin II.
Point Mutation
CRISPR-mediated point mutations can introduce specific amino acid substitutions in the ligand-binding pocket of AGTR1 to test their impact on binding affinity and receptor activation. This approach mimics naturally occurring variants and helps validate mutagenesis data.
Knock-in
Knock-in of tagged receptors (e.g., GFP-AGTR1) or humanized receptor variants enables real-time imaging of receptor trafficking and binding in live cells. This is useful for studying receptor internalization and recycling.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of AGTR1 or AGTR2 can model receptor overactivity in diseases like hypertension and cardiac hypertrophy [1, 2]. Overexpression systems help quantify binding capacity and signaling output.
How EDITGENE Supports angiotensin receptor binding Research
Researchers studying angiotensin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, ligand affinity, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous investigation of GO:0031701 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for angiotensin receptor binding research.
Frequently Asked Questions About angiotensin receptor binding
What is angiotensin receptor binding?
Angiotensin receptor binding (GO:0031701) is the molecular function of a ligand binding to an angiotensin receptor, such as AT1, AT2, or AT4.
What genes are involved in angiotensin receptor binding?
Key genes include AGTR1, AGTR2, ACE, ACE2, REN, and AGT, which encode receptors and ligands in the renin-angiotensin system [1, 7].
What are the main angiotensin receptor subtypes?
The main subtypes are AT1, AT2, and AT4, which bind angiotensin II and angiotensin IV with different affinities and functions [1, 3, 8].
How is angiotensin receptor binding studied?
Common methods include radioligand binding assays, mutagenesis, and CRISPR-based genetic models [4, 5].
What diseases are associated with angiotensin receptor binding?
Hypertension, pulmonary hypertension, kidney disease, and neurological disorders are linked to altered angiotensin receptor binding [2, 3, 5, 7].
What is the role of AT1 receptor in blood pressure?
AT1 receptor binding by angiotensin II causes vasoconstriction and sodium retention, raising blood pressure [1, 7].
How do antihypertensive drugs target angiotensin receptor binding?
Drugs like candesartan block angiotensin II binding to AT1 receptors, preventing vasoconstriction [2, 6].
Can CRISPR be used to study angiotensin receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of receptor-ligand interactions [1, 4].
What is the AT4 receptor?
The AT4 receptor binds angiotensin IV and is involved in memory and neuronal functions.
What is the clinical significance of angiotensin receptor binding?
It is central to cardiovascular homeostasis and a major target for antihypertensive therapy [2, 7].
Conclusion
Angiotensin receptor binding (GO:0031701) is a fundamental molecular function in the renin-angiotensin system, with critical roles in blood pressure regulation and disease. The interaction between angiotensin peptides and their receptors has been extensively characterized through mutagenesis, binding assays, and pharmacological studies [1, 4, 6]. Dysregulated binding contributes to hypertension, pulmonary hypertension, and kidney disease, making it a key therapeutic target [2, 5, 7]. Advances in CRISPR technology now allow precise genetic models to study these interactions in vivo, promising new insights into receptor biology and drug development [1, 4].
References
- 1. Smith RD et al.. 1994. Human angiotensin receptor subtypes.. Curr Opin Nephrol Hypertens 3(1):112-22 PMID: 7850406
- 2. Gleiter CH et al.. 2004. Candesartan.. Cardiovasc Drug Rev 22(4):263-84 PMID: 15592574
- 3. Chai SY et al.. 2004. The angiotensin IV/AT4 receptor.. Cell Mol Life Sci 61(21):2728-37 PMID: 15549174
- 4. Inoue Y et al.. 1997. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism.. J Hypertens 15(7):703-14 PMID: 9222937
- 5. Cassis L et al.. 1997. Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension.. Biochem Pharmacol 54(1):27-31 PMID: 9296348
- 6. Fierensa FL et al.. 2001. Tight binding of the angiotensin AT(1) receptor antagonist.. Biochem Pharmacol 61(10):1227-35 PMID: 11322926
- 7. Edwards RM et al.. 1993. Angiotensin II receptor subtypes in the kidney.. J Am Soc Nephrol 3(10):1643-52 PMID: 8318680
- 8. Timmermans PB et al.. 1992. Angiotensin II receptor subtypes.. Am J Hypertens 5(6 Pt 1):406-10 PMID: 1524767
